GERNNasdaqPharmaceutical PreparationsFiscal year ends December 31
GERON CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$1.20+0.03 (+2.56%)
Close on Oct 19, 2026
- Market cap
- $804.84K
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
76.1%
489M of 642M shares
Institutional holders
260
37 new, 30 sold out
Net institutional buying
-6M
In Q2 2026
Insider trades, 12 months
0 buys · 1 sales
Net sold $19.12K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| RA Capital Healthcare Fund, L.P. | 66,502,728 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
| Deep Track Capital, LP | 43,000,000 | 6.75% | 13G (passive) amendment | Jun 30, 2025 |
| BlackRock, Inc. | 42,172,679 | 7.80% | 13G (passive) amendment | Dec 31, 2023 |
| Soleus Capital Master Fund, L.P. | 41,508,659 | 6.50% | 13G (passive) amendment | Mar 31, 2026 |
| State Street Corporation | 35,856,671 | 5.60% | 13G (passive) | Jun 30, 2026 |
| Soleus Capital Group, LLC | 33,008,659 | 5.20% | 13G (passive) | Feb 25, 2026 |
| Deep Track Biotechnology Master Fund, Ltd. | 32,511,271 | 5.09% | 13G (passive) amendment | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of GERN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 49,115,571 | 7.64% | $62.87M | +1,795,792 | 0.00% |
| Ra Capital Management, L.P. | 42,809,751 | 6.66% | $54.80M | −20,961,615 | 0.48% |
| Soleus Capital Management, L.P. | 42,808,659 | 6.66% | $54.80M | +1,300,000 | 1.89% |
| State Street Corp | 35,856,671 | 5.58% | $45.90M | +5,359,488 | 0.00% |
| Citadel Advisors LLC | 29,038,928 | 4.52% | $37.17M | +7,462,359 | 0.00% |
| Vanguard Capital Management LLC | 27,250,215 | 4.24% | $34.88M | +581,186 | 0.00% |
| Nantahala Capital Management, LLC | 24,450,000 | 3.81% | $31.30M | +13,225,000 | 0.52% |
| Clearbridge Investments, LLC | 19,648,853 | 3.06% | $25.15M | +28,533 | 0.02% |
| Eversept Partners, LP | 18,717,422 | 2.91% | $23.96M | −117,461 | 1.24% |
| Goldman Sachs Group Inc | 16,633,368 | 2.59% | $21.29M | +5,456,777 | 0.00% |
| Geode Capital Management, LLC | 14,555,954 | 2.27% | $18.64M | +885,169 | 0.00% |
| Morgan Stanley | 12,945,431 | 2.01% | $16.57M | +280,312 | 0.00% |
| Vanguard Portfolio Management LLC | 10,812,598 | 1.68% | $13.84M | +6,143,815 | 0.00% |
| Vivo Capital, LLC | 8,671,797 | 1.35% | $11.10M | – | 1.01% |
| Millennium Management LLC | 8,112,267 | 1.26% | $10.38M | +790,745 | 0.00% |
| Kynam Capital Management, LP | 6,836,318 | 1.06% | $8.75M | – | 0.48% |
| Candriam S.C.A. | 5,589,182 | 0.87% | $7.15M | +1,667,706 | 0.03% |
| FMR LLC | 5,502,807 | 0.86% | $7.04M | −1,094,349 | 0.00% |
| Pale Fire Capital SE | 5,307,204 | 0.83% | $6.79M | +418,900 | 0.48% |
| Northern Trust Corp | 5,032,212 | 0.78% | $6.44M | +169,948 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 260 | 489M | 76.1% | 37 / 96 | 62 / 30 | 79M | 85M |
| Q1 2026 | 256 | 497M | 77.4% | 37 / 90 | 56 / 38 | 124M | 69M |
| Q4 2025 | 262 | 479M | 74.5% | 30 / 65 | 99 / 29 | 32M | 62M |
| Q3 2025 | 263 | 509M | 79.2% | 35 / 72 | 89 / 29 | 60M | 66M |
| Q2 2025 | 259 | 515M | 80.1% | 32 / 96 | 72 / 40 | 79M | 74M |
| Q1 2025 | 270 | 510M | 79.4% | 46 / 100 | 66 / 59 | 163M | 140M |
| Q4 2024 | 285 | 489M | 76.2% | 66 / 90 | 65 / 32 | 87M | 107M |
| Q3 2024 | 255 | 510M | 79.4% | 45 / 87 | 59 / 27 | 182M | 91M |
| Q2 2024 | 239 | 465M | 72.4% | 55 / 85 | 51 / 43 | 147M | 123M |
| Q1 2024 | 231 | 443M | 68.9% | 54 / 66 | 64 / 22 | 101M | 64M |
| Q4 2023 | 202 | 406M | 63.1% | 23 / 73 | 47 / 21 | 62M | 28M |
| Q3 2023 | 202 | 371M | 57.8% | 27 / 84 | 34 / 24 | 45M | 18M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of GERN | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 21,816,987 | 3.40% | $27.93M | 0.26% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 20,449,234 | 3.18% | $26.18M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 14,478,730 | 2.25% | $18.53M | 0.02% | Jun 30, 2026 |
| Vanguard Explorer Fund | 12,981,241 | 2.02% | $16.75M | 0.08% | Jul 31, 2026 |
| ClearBridge Small Cap Growth Fund | 6,316,110 | 0.98% | $8.15M | 0.43% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 6,108,370 | 0.95% | $7.82M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 6,100,057 | 0.95% | $7.87M | 0.02% | Jul 31, 2026 |
| Select Biotechnology Portfolio | 5,452,212 | 0.85% | $6.82M | 0.13% | May 31, 2026 |
| iShares Russell 2000 Growth ETF | 5,140,717 | 0.80% | $6.58M | 0.04% | Jun 30, 2026 |
| iShares Biotechnology ETF | 4,426,859 | 0.69% | $5.67M | 0.06% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 2,804,965 | 0.44% | $3.51M | 0.02% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 2,794,804 | 0.44% | $3.49M | 0.01% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 2,555,103 | 0.40% | $3.19M | 0.01% | May 31, 2026 |
| Vanguard Health Care Index Fund | 1,432,603 | 0.22% | $1.79M | 0.01% | May 31, 2026 |
| Schwab Small-Cap Index Fund | 1,360,078 | 0.21% | $1.75M | 0.02% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Harout Semerjian | President and CEO, Director | – | – | Aug 8, 2025 |
| John A. Scarlett | Chairman, President and CEO, Director | 137,500 | 0.02% | Mar 3, 2025 |
| Timothy Williams | EVP and Chief Legal Officer | – | – | Apr 14, 2026 |
| Michelle Robertson | EVP, CHIEF FINANCIAL OFFICER | 27,500 | 0.00% | Feb 19, 2026 |
| Joseph Eid | EVP, R&D; Chief Medical Office | – | – | Feb 19, 2026 |
| Ahmed ElNawawi | EVP, Chief Commercial Officer | 10,000 | 0.00% | Oct 20, 2025 |
| James Ziegler | EVP, Chief Commercial Officer | 100,000 | 0.02% | Mar 3, 2025 |
| Scott Alan Samuels | EVP, Chief Legal Officer | 26,682 | 0.00% | Mar 3, 2025 |
| Andrew J. Grethlein | EVP, Chief Operating Officer | 676,615 | 0.11% | Feb 20, 2025 |
| Robert J. Spiegel | Director | 205,810 | 0.03% | Jul 1, 2026 |
| Dawn Carter Bir | Director | – | – | May 26, 2026 |
| Elizabeth G. O'Farrell | Director | 33,627 | 0.01% | May 26, 2026 |
| Susan Molineaux | Director | 165,527 | 0.03% | May 26, 2026 |
| John F. McDonald | Director | – | – | May 26, 2026 |
| Constantine Chinoporos | Director | – | – | Mar 26, 2026 |
| Patricia S. Andrews | Director | – | – | Mar 26, 2026 |
| V. Bryan Lawlis | Director | 13,300 | 0.00% | May 22, 2025 |
| Gaurav Aggarwal | Director | 1,970 | 0.00% | May 22, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Robert J. Spiegel Director | Jun 30, 2026 | Award | +6,103 | $1.28 | $7.81K | 205,810 |
| Robert J. Spiegel Director | Mar 31, 2026 | Award | +5,243 | $1.49 | $7.81K | 199,707 |
| Michelle Robertson EVP, CHIEF FINANCIAL OFFICER | Feb 18, 2026 | Option exercise | +27,500 | – | – | 27,500 |
| Michelle Robertson EVP, CHIEF FINANCIAL OFFICER | Feb 18, 2026 | Sale | −9,855 | $1.94 | $19.12K | 17,645 |
| Robert J. Spiegel Director | Dec 31, 2025 | Award | +5,918 | $1.32 | $7.81K | 194,464 |
| Robert J. Spiegel Director | Sep 30, 2025 | Award | +5,702 | $1.37 | $7.81K | 188,546 |
| Robert J. Spiegel Director | Jun 30, 2025 | Award | +5,540 | $1.41 | $7.81K | 182,844 |
| V. Bryan Lawlis Director | May 9, 2025 | Buy | +13,300 | $1.18 | $15.69K | 13,300 |
| Robert J. Spiegel Director | Mar 31, 2025 | Award | +4,913 | $1.59 | $7.81K | 177,304 |
| James Ziegler EVP, Chief Commercial Officer | Feb 27, 2025 | Buy | +100,000 | $1.60 | $160.00K | 100,000 |
| Scott Alan Samuels EVP, Chief Legal Officer | Feb 27, 2025 | Buy | +15,000 | $1.61 | $24.15K | 26,682 |
| John A. Scarlett Chairman, President and CEO, Director | Feb 27, 2025 | Buy | +12,500 | $1.77 | $22.13K | 12,500 |
| Robert J. Spiegel Director | Dec 31, 2024 | Award | +2,206 | $3.54 | $7.81K | 172,391 |
| Robert J. Spiegel Director | Dec 31, 2024 | Award | −2,206 | – | – | 172,391 |
| Robert J. Spiegel Director | Sep 30, 2024 | Award | +1,767 | $4.54 | $8.02K | 170,185 |
| Robert J. Spiegel Director | Sep 30, 2024 | Award | −1,767 | – | – | 170,185 |
| Andrew J. Grethlein EVP, Chief Operating Officer | Jul 8, 2024 | Option exercise | +674,348 | $1.72 | $1.16M | 674,348 |
| Andrew J. Grethlein EVP, Chief Operating Officer | Jul 8, 2024 | Sale | −674,348 | $4.56 | $3.08M | 0 |
| Robert J. Spiegel Director | Jun 28, 2024 | Award | +1,916 | $4.24 | $8.12K | 168,418 |
| Robert J. Spiegel Director | Jun 28, 2024 | Award | −1,916 | – | – | 168,418 |
| Faye Feller EVP, Chief Medical Officer | Jun 10, 2024 | Option exercise | +20,000 | $1.06 | $21.20K | 20,000 |
| Faye Feller EVP, Chief Medical Officer | Jun 10, 2024 | Option exercise | +112,500 | $1.06 | $119.25K | 112,500 |
| Faye Feller EVP, Chief Medical Officer | Jun 10, 2024 | Sale | −287,900 | $4.63 | $1.33M | 0 |
| Faye Feller EVP, Chief Medical Officer | Jun 10, 2024 | Option exercise | +155,400 | $1.30 | $202.02K | 155,400 |
| Anil Kapur EVP, Corp Strategy & CCO | Jun 10, 2024 | Sale | −421,875 | $4.65 | $1.96M | 0 |
| Anil Kapur EVP, Corp Strategy & CCO | Jun 10, 2024 | Option exercise | +421,875 | $1.06 | $447.19K | 421,875 |
| John A. Scarlett Chairman, President and CEO, Director | Jun 4, 2024 | Option exercise | +600,000 | $2.54 | $1.52M | 600,000 |
| John A. Scarlett Chairman, President and CEO, Director | Jun 4, 2024 | Sale(10b5-1 plan) | −600,000 | $4.00 | $2.40M | 600,000 |
| V. Bryan Lawlis Director | May 15, 2024 | Option exercise | +35,000 | $1.94 | $67.90K | 35,000 |
| V. Bryan Lawlis Director | May 15, 2024 | Sale(10b5-1 plan) | −35,000 | $3.75 | $131.25K | 0 |
| Robert J. Spiegel Director | Mar 29, 2024 | Award | +2,462 | $3.30 | $8.12K | 166,502 |
| Robert J. Spiegel Director | Mar 29, 2024 | Award | −2,462 | – | – | 166,502 |
| Robert J. Spiegel Director | Dec 29, 2023 | Award | +3,406 | – | – | 164,040 |
| Gaurav Aggarwal Director | Dec 29, 2023 | Award | +1,970 | – | – | 1,970 |
| Susan Molineaux Director | Dec 29, 2023 | Award | +6,220 | – | – | 130,527 |
| Susan Molineaux Director | Sep 29, 2023 | Award | +6,191 | – | – | 124,307 |
| Robert J. Spiegel Director | Sep 29, 2023 | Award | +3,390 | – | – | 160,634 |
| Elizabeth G. O'Farrell Director | Aug 24, 2023 | Buy | +6,579 | $2.28 | $15.00K | 26,220 |
| Elizabeth G. O'Farrell Director | Aug 24, 2023 | Buy | +6,607 | $2.28 | $15.06K | 7,407 |
| Robert J. Spiegel Director | Jun 30, 2023 | Award | +2,239 | – | – | 157,244 |
| Anil Kapur EVP, Corp Strategy & CCO | Jun 30, 2023 | Award | +7,567 | $2.04 | $15.44K | 60,783 |
| Susan Molineaux Director | Jun 30, 2023 | Award | +4,088 | – | – | 118,116 |
| V. Bryan Lawlis Director | May 11, 2023 | Option exercise | +35,000 | $1.10 | $38.50K | 35,000 |
| V. Bryan Lawlis Director | May 11, 2023 | Sale(10b5-1 plan) | −35,000 | $3.00 | $105.00K | 0 |
| Susan Molineaux Director | May 1, 2023 | Option exercise | +35,000 | $1.10 | $38.50K | 35,000 |
| Susan Molineaux Director | May 1, 2023 | Sale(10b5-1 plan) | −35,000 | $2.48 | $86.80K | 0 |
| Susan Molineaux Director | Mar 31, 2023 | Award | +6,048 | – | – | 114,028 |
| Robert J. Spiegel Director | Mar 31, 2023 | Award | +3,312 | – | – | 155,005 |
| John A. Scarlett Chairman, President and CEO, Director | Feb 10, 2023 | Sale(10b5-1 plan) | −446,668 | $3.00 | $1.34M | 0 |
| John A. Scarlett Chairman, President and CEO, Director | Feb 10, 2023 | Option exercise | +446,668 | $1.50 | $670.00K | 446,668 |
| John A. Scarlett Chairman, President and CEO, Director | Feb 9, 2023 | Option exercise | +446,666 | $1.50 | $670.00K | 446,666 |
| John A. Scarlett Chairman, President and CEO, Director | Feb 9, 2023 | Sale(10b5-1 plan) | −446,666 | $3.03 | $1.35M | 0 |
| Andrew J. Grethlein EVP, Chief Operating Officer | Feb 9, 2023 | Sale(10b5-1 plan) | −234,719 | $3.03 | $711.20K | 0 |
| Andrew J. Grethlein EVP, Chief Operating Officer | Feb 9, 2023 | Option exercise | +150,000 | $1.51 | $226.50K | 384,719 |
| Andrew J. Grethlein EVP, Chief Operating Officer | Feb 9, 2023 | Sale(10b5-1 plan) | −150,000 | $3.03 | $454.50K | 234,719 |
| John A. Scarlett Chairman, President and CEO, Director | Feb 8, 2023 | Option exercise | +446,666 | $1.50 | $670.00K | 446,666 |
| John A. Scarlett Chairman, President and CEO, Director | Feb 8, 2023 | Sale(10b5-1 plan) | −446,666 | $3.08 | $1.38M | 0 |
| Olivia Kyusuk Bloom EVP, Chief Financial Officer | Feb 8, 2023 | Sale(10b5-1 plan) | −400,000 | $3.08 | $1.23M | 74,588 |
| Olivia Kyusuk Bloom EVP, Chief Financial Officer | Feb 8, 2023 | Option exercise | +400,000 | $1.51 | $604.00K | 474,588 |
| Karin Eastham Director | Jan 13, 2023 | Option exercise | +35,000 | $1.10 | $38.50K | 109,047 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Ziegler James Officer | Dec 15, 2025 | 20,000 | $27.40K | Dec 15, 2025 | Open Market Purchase |
| Andrew J. Grethlein Officer | Jul 8, 2024 | 674,348 | $2.93M | Jul 8, 2024 | STOCK OPTION EXERCISE |
| Anil Kapur Officer | Jun 10, 2024 | 421,875 | $1.96M | Jun 10, 2024 | STOCK OPTION EXERCISE |
| Faye Feller Officer | Jun 10, 2024 | 287,900 | $1.34M | Jun 10, 2024 | STOCK OPTION EXERCISE |
| A. Scarlett John Officer, Director | Jun 4, 2024 | 600,000 | $2.40M | Jun 4, 2024 | Stock Option Exercise |
| Lawlis Bryan Jr. Director | May 15, 2024 | 35,000 | $131.27K | May 15, 2024 | Stock Option Exercise |
| Lawlis Bryan Jr Director | May 11, 2023 | 35,000 | $105.00K | May 11, 2023 | Stock Option Exercise |
| Molineaux Susan Director | May 1, 2023 | 35,000 | $86.65K | May 1, 2023 | Stock Options |